NCT05101070 2026-03-18
aCCeleR8-001
Shionogi Inc.
Phase 1/2 Recruiting
Clinical Trials
25 trialsNCT05203172 2026-03-18
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
NCT05155332 2026-03-17
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
NCT06892379 2026-03-13
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT04261413 2026-03-11
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Phase 1 Completed
NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT03313778 2026-03-04
KEYNOTE-603
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT03448042 2026-02-27
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT07176975 2026-02-27
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Not yet recruiting
NCT07030959 2026-02-25
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
Phase 1 Recruiting
NCT04250155 2026-02-24
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT07181681 2026-02-23
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07123103 2026-02-17
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Recruiting
NCT07415031 2026-02-17
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT06885281 2026-02-13
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1/2 Recruiting
NCT02320435 2026-02-12
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03917381 2026-02-11
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT07395258 2026-02-09
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Not yet recruiting
NCT05982873 2026-02-06
Expanded Access to Telisotuzumab Adizutecan
AbbVie
Available
NCT05372367 2026-02-03
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
Phase 1 Completed
NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT00777582 2026-01-13
Phase I Comparative Bioavailability Study
AstraZeneca
Phase 1 Active not recruiting
NCT07312903 2026-01-12
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
Phase 1 Recruiting
NCT07265622 2025-12-29
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06227377 2025-12-24
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
Phase 1 Recruiting